366 related articles for article (PubMed ID: 8229153)
1. No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies.
Bacci G; Picci P; Ruggieri P; Ferrari S; Mercuri M; Fabbri N; Rosito P; Barbieri E; Ferraro A; Casadei R
J Chemother; 1993 Aug; 5(4):247-57. PubMed ID: 8229153
[TBL] [Abstract][Full Text] [Related]
2. [Neoadjuvant treatment of Ewing's sarcoma: results obtained in 122 patients treated with a 6-drug chemotherapeutic protocol (vincristine, adriamycin, cyclophosphamide, dactinomycin, ifosfamide and etoposide)].
Bacci G; Ferrari S; Rosito P; Barbieri E; Mercuri M; Brach del Prever A; Iantorno D; Forni C; Campanacci M
Minerva Pediatr; 1995 Nov; 47(11):457-69. PubMed ID: 8684341
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
Bacci G; Picci P; Ferrari S; Mercuri M; Brach del Prever A; Rosito P; Barbieri E; Tienghi A; Forni C
Cancer; 1998 Mar; 82(6):1174-83. PubMed ID: 9506366
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
[TBL] [Abstract][Full Text] [Related]
5. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial.
Dunst J; Jürgens H; Sauer R; Pape H; Paulussen M; Winkelmann W; Rübe C
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):919-30. PubMed ID: 7607966
[TBL] [Abstract][Full Text] [Related]
6. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
[TBL] [Abstract][Full Text] [Related]
7. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group.
Donaldson SS; Torrey M; Link MP; Glicksman A; Gilula L; Laurie F; Manning J; Neff J; Reinus W; Thompson E; Shuster JJ
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):125-35. PubMed ID: 9747829
[TBL] [Abstract][Full Text] [Related]
8. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
Miser JS; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Grier HE
J Clin Oncol; 2004 Jul; 22(14):2873-6. PubMed ID: 15254055
[TBL] [Abstract][Full Text] [Related]
9. [Therapy of non-metastatic Ewing's sarcoma (pelvis excluded). Results obtained in 48 cases combining local therapy (radiation and/or surgical) and adjuvant chemotherapy with vincristine, adriamycin, dactinomycin and cyclophosphamide].
Sudanese A; Avella M; Toni A; Boriani S; Baldini N; Monesi M; Battistini A; Mancini A; Campanacci M
Minerva Med; 1987 Apr; 78(7):473-82. PubMed ID: 3574734
[TBL] [Abstract][Full Text] [Related]
10. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
Tural D; Molinas Mandel N; Dervisoglu S; Oner Dincbas F; Koca S; Colpan Oksuz D; Kantarci F; Turna H; Selcukbiricik F; Hiz M
Jpn J Clin Oncol; 2012 May; 42(5):420-6. PubMed ID: 22416252
[TBL] [Abstract][Full Text] [Related]
11. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.
Paulussen M; Ahrens S; Dunst J; Winkelmann W; Exner GU; Kotz R; Amann G; Dockhorn-Dworniczak B; Harms D; Müller-Weihrich S; Welte K; Kornhuber B; Janka-Schaub G; Göbel U; Treuner J; Voûte PA; Zoubek A; Gadner H; Jürgens H
J Clin Oncol; 2001 Mar; 19(6):1818-29. PubMed ID: 11251014
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.
Meyer WH; Kun L; Marina N; Roberson P; Parham D; Rao B; Fletcher B; Pratt CB
J Clin Oncol; 1992 Nov; 10(11):1737-42. PubMed ID: 1403056
[TBL] [Abstract][Full Text] [Related]
13. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Kushner BH; Meyers PA
J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli.
Bacci G; Ferrari S; Bertoni F; Donati D; Bacchini P; Longhi A; Brach Del Prever A; Forni C; Rimondini S
J Clin Oncol; 2000 Feb; 18(4):885-92. PubMed ID: 10673532
[TBL] [Abstract][Full Text] [Related]
15. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
[TBL] [Abstract][Full Text] [Related]
16. Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.
Ataergin S; Ozet A; Solchaga L; Turan M; Beyzadeoglu M; Oysul K; Arpaci F; Komurcu S; Surenkok S; Ozturk M
Med Oncol; 2009; 26(3):276-86. PubMed ID: 18989798
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma.
Bacci G; Picci P; Mercuri M; Ferrari S; Longhi A; Cesari M; Rosito P; Mancini AF; Barbieri E; Baldini N
Acta Oncol; 1998; 37(7-8):671-6. PubMed ID: 10050985
[TBL] [Abstract][Full Text] [Related]
18. Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP).
Deméocq F; Oberlin O; Benz-Lemoine E; Boilletot A; Gentet JC; Zucker JM; Behar C; Poutard P; Olive D; Brunat-Mentigny M
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S45-7. PubMed ID: 2667789
[TBL] [Abstract][Full Text] [Related]
19. [The type of local treatment conditions the prognosis in patients with nonmetastatic Ewing's sarcoma of the extremities treated with adjuvant chemotherapy].
Bacci G; Ferrari S; Rosito P; Barbieri E; Mercuri M; Iantorno D; Brach Del Prever A; Ruggieri P; Forni C
Minerva Chir; 1997 Apr; 52(4):415-26. PubMed ID: 9265127
[TBL] [Abstract][Full Text] [Related]
20. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
Dunst J; Ahrens S; Paulussen M; Rübe C; Winkelmann W; Zoubek A; Harms D; Jürgens H
Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):379-84. PubMed ID: 9788419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
